Actively Recruiting

Phase 4
Age: 18Years - 65Years
All Genders
ID06223880

A Randomized, Double-blind, Active-controlled Study of AXS-05 Compared to Bupropion for Preventing Relapse of Depressive Symptoms in Major Depressive Disorder

Led by Axsome Therapeutics, Inc. · Updated on 2025-01-23

350

Participants Needed

40

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating the effectiveness of AXS-05 compared to bupropion in preventing the return of depressive symptoms in adults with major depressive disorder (MDD) who have already responded to treatment with AXS-05. This is a randomized, double-blind, active-controlled study conducted across multiple centers, aiming to assess relapse prevention in people diagnosed with MDD without psychotic features. Participants will first receive open-label AXS-05 treatment for up to 10 weeks, during which their response and remission will be monitored. Those who meet response and remission criteria will then be randomly assigned to continue taking AXS-05 or switch to bupropion tablets, both taken twice daily, for a double-blind treatment period lasting up to 26 weeks or until depressive symptoms relapse. Throughout the study, participants will be closely monitored for signs of depressive symptom relapse using regular assessments. The main outcome measured is the time from randomization to relapse over the 26-week double-blind period. The entire study period includes an initial 10-week treatment phase followed by up to 26 weeks of randomized treatment, with ongoing evaluation by the study team to track safety and treatment effects.

CONDITIONS

Brief Title

A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms

Who Can Participate

Age: 18Years - 65Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Currently meets DSM-5 criteria for diagnosis of major depressive disorder without psychotic features
  • Has a current major depressive episode lasting at least 4 weeks
  • Is between 18 and 65 years old
Not Eligible

You will not qualify if you...

  • Previously participated in another clinical study of AXS-05
  • Received any investigational drug or device treatment within 30 days before screening
  • Has been prescribed Auvelity
  • Unable to comply with study procedures
  • Medically inappropriate for study participation as judged by the investigator or doctor in charge of the study care team

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Open-label Treatment

Duration - Up to 10 weeks

Participants receive open-label AXS-05 and are monitored for response and remission of depressive symptoms.

Regular visits during treatment period

Double-blind Treatment

Duration - Up to 26 weeks or until relapse

Participants who respond to open-label treatment are randomized to continue AXS-05 or switch to bupropion to prevent relapse of depressive symptoms.

Regular visits during treatment period

Trial Site Locations

Total: 40 locations

1

Clinical Research Site

Bellflower, California, United States, 90706

Actively Recruiting

2

Clinical Research Site

Lafayette, California, United States, 94549

Actively Recruiting

3

Clinical Research Site

Oceanside, California, United States, 92056

Actively Recruiting

4

Clinical Research Site

Redlands, California, United States, 92374

Actively Recruiting

5

Clinical Research Site

Riverside, California, United States, 92506

Actively Recruiting

6

Clinical Research Site

San Diego, California, United States, 92103

Actively Recruiting

7

Clinical Research Site

Upland, California, United States, 91786

Actively Recruiting

8

Clinical Research Site

Brandon, Florida, United States, 33511

Actively Recruiting

9

Clinical Research Site

Doral, Florida, United States, 33122

Actively Recruiting

10

Clinical Research Site

Hialeah, Florida, United States, 33012

Actively Recruiting

11

Clinical Research Site

Jacksonville, Florida, United States, 32256

Actively Recruiting

12

Clinical Research Site

Miami, Florida, United States, 33122

Actively Recruiting

13

Clinical Research Site

Orlando, Florida, United States, 32801

Actively Recruiting

14

Clinical Research Site

Orlando, Florida, United States, 32806

Actively Recruiting

15

Clinical Research Site

Orlando, Florida, United States, 32807

Actively Recruiting

16

Clinical Research Site

Atlanta, Georgia, United States, 30331

Actively Recruiting

17

Clinical Research Site

Chicago, Illinois, United States, 60634

Actively Recruiting

18

Clinical Research Site

Overland Park, Kansas, United States, 66210

Actively Recruiting

19

Clinical Research Site

New Orleans, Louisiana, United States, 70115

Actively Recruiting

20

Clinical Research Site

Boston, Massachusetts, United States, 02131

Actively Recruiting

21

Clinical Research Site

Saint Charles, Missouri, United States, 63304

Actively Recruiting

22

Clinical Research Site

Las Vegas, Nevada, United States, 89102

Actively Recruiting

23

Clinical Research Site

Cherry Hill, New Jersey, United States, 08002

Actively Recruiting

24

Clinical Research Site

Toms River, New Jersey, United States, 08755

Actively Recruiting

25

Clinical Research Site

Brooklyn, New York, United States, 11235

Actively Recruiting

26

Clinical Research Site

Mount Kisco, New York, United States, 10549

Actively Recruiting

27

Clinical Research Site

New York, New York, United States, 10128

Actively Recruiting

28

Clinical Research Site

Staten Island, New York, United States, 10314

Actively Recruiting

29

Clinical Research Site

Hickory, North Carolina, United States, 28601

Actively Recruiting

30

Clinical Research Site

Cincinnati, Ohio, United States, 45215

Actively Recruiting

31

Clinical Research Site

Edmond, Oklahoma, United States, 73013

Actively Recruiting

32

Clinical Research Site

Oklahoma City, Oklahoma, United States, 73118

Actively Recruiting

33

Clinical Research Site

Portland, Oregon, United States, 97210

Actively Recruiting

34

Clinical Research Site

Memphis, Tennessee, United States, 38119

Actively Recruiting

35

Clinical Research Site

Dallas, Texas, United States, 75231

Actively Recruiting

36

Clinical Research Site

Dallas, Texas, United States, 75243

Actively Recruiting

37

Clinical Research Site

Friendswood, Texas, United States, 77546

Actively Recruiting

38

Clinical Research Site

San Antonio, Texas, United States, 78229

Actively Recruiting

39

Clinical Research Site

Wichita Falls, Texas, United States, 76309

Actively Recruiting

40

Clinical Research Site

Everett, Washington, United States, 98201

Actively Recruiting

Loading map...

Research Team

S

Study Director

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Similar Trials

A Phase III, Placebo-Controlled, Randomized, Double-Blind Tr...

Major Depressive Disorder

Actively Recruiting

46 locations

A Double-blinded, Randomized Placebo-controlled Trial of 40 ...

Major Depressive Disorder

Actively Recruiting

1 location

31P-MRS and Functional Connectivity Study of 5-HTP and Creat...

Major Depressive Disorder

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here